Francis Richard D sold 250,000 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD at $42.24 for −$10.6M on Nov 10, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
President and CEO
President and CEO
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$10,559,175Shares × reported price
Shares traded
250,000Ordinary Shares
Price per share
$42.24Reported price. Read footnotes for ranges.
% of reported position traded
21.23%This security and ownership context
Holdings after
927,529Direct
Trade date
Nov 10, 2026Sell
Filed
Nov 12, 2026, 4:13 PM ET2-day reporting delay
Accession
0001193125-26-458424Code S · Transaction 398850
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 1,177,529 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5.8%1w ago −7%1d ago −1.6%
Returns since7d30d90d180d1y

Footnotes in full

F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.755 to $42.69, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.